Self-Assessment Post-Test

SELF-ASSESSMENT POST-TEST Complete the following by circling the correct answer below. Prostate Cancer: Progression, Risk Reduction, and Future Options 1. A family history of prostate cancer in a father and brother increases a man’s risk of developing prostate cancer by: a. A negligible amount b. Double c. Triple d. Quadruple e. More than 5 times 2. Cancers associated with the HPC1 gene: a. Occur most frequently in families with few affected family members b. Occur predominantly in men over age 70 years c. Are caused by a viral infection d. Account for the majority of sporadic prostate cancers e. Are associated with aggressive clinical features 3. 4. 5. 6. 7. Since the introduction of prostate-specific antigen (PSA) in the late 1980s, which pattern describes prostate cancer–related mortality in U.S. men? African Americans Caucasians a. Increasing Decreasing b. Decreasing Increasing c. Stable Increasing d. Stable Decreasing e. Increasing Stable The Selenium and Vitamin E Cancer Prevention Trial is based on observations that selenium and vitamin E: a. Inhibit the growth of prostate cancer cell lines b. May reduce the incidence and mortality of prostate cancer c. Decrease serum PSA d. Eliminate high-grade prostate intraepithelial neoplasia (PIN) on biopsy e. Increase the likelihood of organ-confined disease at radical prostatectomy The enzyme 5-α reductase: a. Is mutated in men with HPC1-associated cancers b. Is stimulated by finasteride c. Converts testosterone to dihydrotestosterone (DHT) d. Causes prostate cancer when overactive e. Is inhibited by selenium All of the following have been associated with an increased risk of developing prostate cancer EXCEPT: a. Positive family history b. A diet rich in lycopene c. Mutations in the ribonuclease L (RNaseL) enzyme d. A high-fat diet e. Calcium deficiency All of the following represent examples of primary chemoprevention EXCEPT: a. Reducing dietary fat intake b. Progestins to prevent uterine cancer c. Fluoride to prevent tooth decay d. Statins to prevent arteriosclerosis e. Estrogens to prevent osteoporosis 8. In the Olmsted County Study of Urinary Symptoms and Health Status Among Men, longitudinal declines in peak urinary flow rates were associated with: a. Lower baseline scores on the International Prostate Symptom Score (IPSS) b. Smaller prostate size c. Use of dietary supplements d. Serum DHT levels e. Advancing age 9. Finasteride inhibits the function of: a. RNaseL b. Steroid hormone–binding globulin c. Cyclooxygenase 1 (COX-1) d. Cyclooxygenase 2 (COX-2) e. Type II 5-α reductase 10. The risk of developing acute urinary retention is associated with all of the following EXCEPT: a. Age b. Prostate volume c. Urinary urgency d. Serum PSA level e. IPSS score 11. With long-term use, finasteride lowers the risk of developing: a. High-grade PIN b. Urinary retention c. Symptomatic chronic prostatitis d. Proliferative inflammatory atrophy e. Prostate cancer 12. “Secondary chemoprevention” implies: a. Prevention of second primary malignancies b. Concurrent use of two preventive agents c. Prevention of cancer in at-risk family members d. Prevention of cancer-related complications e. Prevention of progression to a new disease state 13. The HPC1 enzyme RNaseL: a. Causes apoptosis b. Is mutated in most men with prostate cancer c. Is inhibited by selenium and vitamin E d. Is regulated by androgens e. Is inactive in men with benign prostatic hyperplasia 14. The primary endpoint of the Prostate Cancer Prevention Trial is the: a. Long-term toxicity of finasteride b. Prostate cancer–related mortality c. Prevalence of prostate cancer d. Effects of finasteride on PIN e. Predictive value of PSA velocity and PSA density 15. The most active isoflavone in soy products is: a. Glutathione-S-transferase b. COX-2 c. Saw palmetto d. Genistein e. Lycopene VOL. 4 SUPPL. 5 2002 REVIEWS IN UROLOGY S39 REGISTRATION Prostate Cancer: Progression, Risk Reduction, and Future Options Name Title Address City State Zip Fax E-Mail Specialty Phone COURSE EVALUATION Using a five-point scale (5 = strongly agree; 4 = agree; 3 = uncertain; 2 = disagree; 1 = strongly disagree), please answer the following evaluation questions. __ __ __ __ __ The content seemed current. The program content was relevant to my practice. Overall, the supplement provided a valuable learning experience. My personal objectives in reading this supplement were fulfilled. The supplement was presented as a fair and balanced discussion and was not commercial in nature. The NYU Post-Graduate Medical School designates this educational activity for a maximum of 2 hours in Category 1 credit toward the AMA Physician’s Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity. Signature Credit Hours (not to exceed 2 hours) I would be interested in attending a CME program on this topic in my area. Mail To: NYU Post-Graduate Medical School 550 First Avenue, SLH 4-20-O New York, NY 10016 Attn: Joann Carpana Or Fax To: 212.263.5293 Additional Comments: Release Date: November 30, 2002 Expiration: Credit will be awarded for required materials postmarked or received no later than November 30, 2003. Certificates will be mailed within one month of receipt of these materials. S40 VOL. 4 SUPPL. 5 2002 REVIEWS IN UROLOGY